For instance, TNBC patients bearing mutations in PIK3CA, AKT1, and ESR1, as well as EGFR amplifications, may be treated with different drugs to those that are used to treat other subtypes of breast cancer (BRCA) and Non-Small Cell Lung Cancer (NSCLS), respectively. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.